Disturbance of inorganic phosphate metabolism in diabetes mellitus: Temporary therapeutic intervention trials

Diabetes, Metabolic Syndrome and Obesity

Volumn 2, Issue , 2009, Pages 173-177

  Ditzel, Jørn ^a   Lervang, Hans Henrik ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diabetes; Early intervention trials; Inorganic phosphate metabolism

Indexed keywords

CALCIUM PYROPHOSPHATE; ETIDRONIC ACID; FRUCTOSE 1,6 BISPHOSPHATE; INSULIN; PHOSPHATE; PLACEBO;

BLOOD GLUCOSE MONITORING; DIABETES CONTROL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOXEMIA; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; REVIEW;

EID: 77953452329     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s6338     Document Type: Review

References (40)

1. Ditzel J. Effect of plasma inorganic phosphate on tissue oxygenation during recovery from diabetic ketoacidosis. Adv Exp Med Biol. 1973;37A:163-172.
2. Ditzel J, Standl E. The problem of tissue oxygenation in diabetes mellitus. II Evidence of disordered oxygen release from the erythrocytes of diabetics in various conditions of metabolic control. Acta Med Scand. 1975;Suppl 578:S59-S68.
3. Ditzel J, Brøchner-Mortensen J, Rødbro P. Elevated glomerular filtration rate in early diabetes may be explained by increased sodium reabsorption secundary to impairment in renal tubular handling of phosphate. Hormone Metab Res. 1981;Suppl 11:S87-S89.
4. Ditzel J, Brøchner-Mortensen J, Kawahara R. Dysfunction of tubular phosphate reabsorption related to glomerular filtration and blood glucose control in diabetic children. Diabetologia. 1982;23(5): 406-410.
5. Ditzel J, Brøchner-Mortensen J. Tubular reabsorption rates as related to elevated glomerular filtration in diabetic children. Diabetes. 1983; 32 Suppl 2:S28-S32.
6. Mathiassen B, Nielsen S, Johansen JS, et al. Long-term bone loss in insulin-dependent diabetic patients with microvascular complications. J Diabet Complications. 1990;4(4):145-149.
7. Hardy HA, Wellman M. Oxidative phosphorylation. Role of inorganic phosphate and acceptor systems in control of metabolic rates. J Biol Chem. 1952;185:215-224.
8. Sestoft L. Regulation of fructose metabolism in the perfused rat liver. Interrelation with inorganic phosphate, glucose, ketone body and ethanol metabolism. Biochem Biophys Acta. 1974;343(1):1-16.
9. Brazy PC, Mandel IJ. Does availability of inorganic phosphate regulate cellular oxidative metabolism? News Physiol Sci. 1986;1:100-103.
10. Bose S, French S, Evans FJ, Balaban RS. Metabolic network control of oxidative phosphorylation: Multiple roles of inorganic phosphate. J Biol Chem. 2003;278(40):39155-39165.
11. Sestoft L. Is the relationship between plasma concentration of inorganic phosphate and the rate of oxygen consumption of significance in regulating energy metabolism in mammals? Scand J Clin Invest. 1979;39(3):191-197.
12. Firmat G, Prunier J, Rawson RW, Roberts KE, Schwartz MK. Effect of phosphate enhancing the action of triiodothyronine. Endocrinology. 1956;59(5):565-570.
13. Mosekilde L, Christensen MS. Decreased parathyroid function in hyperthyroidism: interrelationshipp between parathyroid hormone, calcium-phosporous metabolism and thyroid function. Acta Endocrinol (Copenh). 1977;84(3):566-575.
14. Ditzel J, Standl E. Plasma Pi and erythrocyte 2, 3DPG concentrations of non-acidotic diabetics in various degree of metabolic control. Clin Chem. 1976;22(4):550-551.
15. Ditzel J, Jæger P, Standl E. An adverse effect of insulin on the oxygen-release capacity of red blood cells in nonacidotic diabetics. Metabolism. 1978;27(8):927-934.
16. Gertner JM, Tamborlane WV, Horst RL, Sherwin RS, Felig P, Genel M. Mineral metabolism in diabetes mellitus. Changes accompanying treatment with portable subcutaneous insulin infusion. J Clin Endocrinol Metab. 1980;50(5):862-866.
17. Raskin P, Pak CYC. The effect of chronic insulin therapy on phosphate metabolism in diabetes mellitus. Diabetologia. 1981;21(1):50-53.
18. Nagasaka S, Murakami T, Uchikawa T, Ishikawa SE, Sato T. Effect of glycemic control on calcium and phosphorous handling and parathyroid level in patients with non-insulin-depemdemt diabetes mellitus. Endocr J. 1995;42(3):377-383.
19. Ditzel J. The problem of tissue oxygenation in diabetes mellitus III. Acta Med Scand. 1975;Suppl 578:S69-S83.
20. Ditzel J, Lervang HH, Brøchner-Mortensen J, Rødbro P. The influence of a dietary supplement of calcium and phosphate on bone mineral content and mineral homeostasis of diabetic children. Diabetologia. 1993;Suppl 1:A58.
21. Altman RD, Johnson CC, Khairi MRA, Wellman M, Serafini AN, Sankey RR. Influence of disodium etidronate (EHDPTM) on clinical and laboratory manifestastion of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973;289(26):1379-1384.
22. Recker RR, Hassing GS, Lau JR, Saville PD. The hyperphosphatemic effect of disodium-1-hydroxy-1, 1 diphophonate (EHDPTM): Renal handling of phosphorus and the renal response to parathyroid hormone. J Lab Clin Med. 1973;81(2):258-266.
23. Russell RGG, Smith R, Preston C, Walton RJ, Woods CG. Diphosphonates in Paget's disease. Lancet. 1974;1(7863):894-898.
24. Ditzel J, Hau C, Daugaard N. Effect of diphosphonate ethane-1-hydroxy-1, 1-diphosphonate (EHDP) on hemoglobin oxygen affinity of diabetic and healthy subjects. Microvasc Res. 1977;13(4):355-361.
25. Nielsen NV, Ditzel J, Jensen S, Kjærgaard JJ. The effect of etidronate disodium (EHDP) on retinopathy in insulin-dependent diabetic patients. Graefe's Arch Clin Exp Ophthalmol. 1982;219(2):60-63.
26. Natelson S, Klein M, Kramer B. The effect of oral administration of calcium fructose diphosphate on the serum organic phosphate, inorganic phosphate, calcium protein, and citric acid levels. J Clin Invest. 1951(1);30:50-54.
27. Hardin C, Lazzarino G, Tavazzi B, Di Pierro D, Roberts TM, Giardino B, et al. Myocardial metabolism of exogenous FDP is consistent with transport by a dicarboxylate transporter. Am J Physiol. 2001;281(6):H2654-H2660.
28. Markow AK, Neely WA, Didioki RH, TerryIII J, Causey A, Lehan PH. Metabolic responses of Fructose-1, 6-diphosphate in healthy subjects. Metabolism. 2000;49(6):698-703.
29. Ehringer WD, Niu W, Chiang B, Wang OL, Gordon L, Chien S. Membrane permeability of fructose.1, 6.diphosphate in lipid vesicles and endothelial cells. Mol Cell Biochem. 2000;210(1-2):35-45.
30. Takeuchi K, Cao-Danh H, Frichs I, Glynn P, DÀgostino D, Simplaceanu E, et al. Administration of fructose 1,6-diphosphate during early reperfusion significantly improves recovery of contractile function in the postischemic heart. J Thorac Cardiovasc Surg. 1998;116(2): 335-339.
31. Antunes N, Martinusso CA, Takiya CM, de Silva AJR, de Omellas JFR Elias PR, et al. Fructose-1, 6 diphosphate as a protective agent for experimental ischemic acute renal failure. Kidney Int. 2006;69(1): 68-72.
32. Rao MR, Olinde KD, Markov AK. In vitro induction of nitric oxide by fructose-1, 6-diphosphate in the cardiovascular system of rats. Mol Cell Biochem. 1998;185(1-2):171-175.
33. Cacioli D, Clivate A, Pelosi P, Megevand J, Galeone M. Haemorheological effects of fructose-1, 6-diphosphate in patients with lower extremity ischemia. Curr Med Res Opin. 1988;10(10):668-674.
34. Urso L, Brillante C, Orlandi M, Rotundo M, Ballati S. Evaluation of fructose-1, 6-diphosphate on erythrocyte 2, 3 diphosphoglycerate and ATP in surgical orthopedic patients. Aggressologie. 1982;23(3):115-117.
35. Barrett PQ, Aronson PS. Glucose and alanine inhibition of phosphate transport in renal microvillus membrane vesicles. Am J Physiol. 1982;242(2):F126-F131.
36. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
37. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet. 1998;352(9131):837-853.
38. Christoffersen J, Christoffersen NR, Ruben J, Arenda J. The effect of EHDP concentration on enamel demineralization in vitro. J Dent Res. 1991;70(2):123-126.
39. Hirano T, Turner CH, Forwood HR, Johnson CC, Burr DR. Does suppression bone turnover impair mechanical properties by allowing microdamage accumulation? Bone. 2000;27(1):13-20.
40. Håglin L, Lindblad A, Bygren LO. Hypophosphataemia in the metabolic syndrome. Gender differences in body weight and blood glucose. Eur J Clin Nutr. 2001;55(6):493-498.